Skip to Content
Merck
CN
  • Analysis of total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human urine.

Analysis of total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human urine.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2003-12-04)
Steven G Carmella, Shaomei Han, Anne Fristad, Yiying Yang, Stephen S Hecht
ABSTRACT

A new method was developed for the analysis of metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human urine. The metabolites are 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and its glucuronides (NNAL-O-Gluc and NNAL-N-Gluc). The sum of these metabolites, total NNAL, was measured with this method. Urine was treated with beta-glucuronidase, which converts NNAL-O-Gluc and NNAL-N-Gluc to NNAL. After solvent partitioning and further purification on a liquid-liquid extraction cartridge and by high-performance liquid chromatography, total NNAL was quantified by gas chromatography with nitrosamine selective detection. The new method is accurate and precise, and the results are in good agreement with those obtained using the traditional method, which quantifies NNAL and its glucuronides separately. Levels of total NNAL +/- SD (pmol/mg creatinine) were 2.60 +/- 1.30 (n = 41) in smokers, 3.25 +/- 1.77 (n = 55) in snuff-dippers, and 0.042 +/- 0.020 (n = 18) in nonsmokers exposed to environmental tobacco smoke. The new method is faster and more sensitive than the traditional method and should greatly facilitate studies on human uptake of NNK.